DAX25.204 +1,4%Est506.086 +0,8%MSCI World4.343 -0,1%Top 10 Crypto8,7200 +2,0%Nas23.066 -0,2%Bitcoin57.253 +1,5%Euro1,1885 +0,1%Öl68,73 -1,3%Gold5.079 -0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Siemens Energy ENER6Y SAP 716460 Rheinmetall 703000 Mercedes-Benz Group (ex Daimler) 710000 Deutsche Telekom 555750 Gerresheimer A0LD6E Siemens 723610 NVIDIA 918422 BASF BASF11 Lufthansa 823212 Allianz 840400 Microsoft 870747 Amazon 906866 Commerzbank CBK100 Bayer BAY001
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX fester -- Mercedes-Benz: Gewinneinbruch -- Siemens erhöht Ergebnisprognose -- TKMS, Deutsche Börse, DroneShield, Novo Nordisk, Viking, Lufthansa, Birkenstock, Micron, Palantir im Fokus
Top News
Palantir-Aktie fester: Freigabe für Einsatz an der Front untermauert Führungsrolle Palantir-Aktie fester: Freigabe für Einsatz an der Front untermauert Führungsrolle
Ausblick: Airbnb informiert über die jüngsten Quartalsergebnisse Ausblick: Airbnb informiert über die jüngsten Quartalsergebnisse
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Noch bis 14. April bei der Commerzbank gebührenfrei in Vanguard-ETFs investieren

AbbVie Aktie

Kaufen
Verkaufen
AbbVie Aktien-Sparplan
186,00 EUR +0,20 EUR +0,11 %
STU
221,00 USD -1,40 USD -0,63 %
vorbörslich
BTT
AbbVie jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.331,15 Mrd. EUR

KGV95,86Div. Rendite2,91%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1J84E

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00287Y1091

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolABBV

AbbVie Aktien News

DatumMeistgelesen
PR NewswireHealth Canada Approves ELAHERE® for Certain Types of Platinum-Resistant Ovarian Cancers
PR NewswireHealth Canada Approves ELAHERE® for Certain Types of Platinum-Resistant Ovarian Cancers
PR NewswireAbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
PR NewswireAbbVie Named to 2025 Best Workplaces in Asia List by Great Place To Work
PR NewswireRINVOQ® (upadacitinib) Receives Health Canada Notice of Compliance (NOC) for Giant Cell Arteritis in adults
PR NewswireAbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline
PR NewswireAbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
PR NewswireAbbVie Completes Acquisition of Capstan Therapeutics
PR NewswireSkinMedica® Unveils Its Newest Hydration Hero
PR NewswireAbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.
PR NewswireGet Ready, JUVÉDERM® Day is Calling!
PR NewswireAbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
PR NewswireAbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
PR NewswireBOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Project
PR NewswireAbbVie's 10th 'Week of Possibilities' Unites Employees Across Asia for Community Impact
PR NewswireRefresh Releases First of its Kind Eye Drop for Dry Eyes
PR NewswireIchnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
PR NewswireAbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
PR NewswireAbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology
PR NewswireU.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
PR NewswireAbbVie to Host Second-Quarter 2025 Earnings Conference Call
PR NewswireAbbVie Declares Quarterly Dividend
PR NewswireAbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention
PR NewswireAbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
PR NewswireU.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus
PR NewswireAbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals
PR NewswireAbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
PR NewswireAbbVie Partners with Chicago Cubs on "Striking Out Cancer"
PR NewswireClass Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors - Contact The Gross Law Firm
PR NewswireAbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio
PR NewswireAbbVie and U of T Mississauga's SpinUp Announce Neuropeutics Inc as First AbbVie Biotech Innovators Award Recipient
PR NewswireShareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact Levi & Korsinsky about pending Class Action - ABBV
PR NewswireAbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas
PR NewswireAbbVie to Present at the Bank of America Securities Healthcare Conference
PR NewswireRINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)
PR NewswireAbbVie Reports First-Quarter 2025 Financial Results
PR NewswireAbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines
PR NewswireAbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis
PR NewswireAbbVie to Host First-Quarter 2025 Earnings Conference Call
PR NewswireAbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025

AbbVie News

AbbVie News: auf dieser Seite finden Sie alle AbbVie News und Nachrichten zur AbbVie Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch AbbVie News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um AbbVie News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.